VTRS

$19.040.86%-0.165

Pre-mercato: 19.00-0.04 -0.18%

Viatris Inc (VTRS)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$19.20

Aprire:

$19.29

Volume 24 ore:

8,792,669

Volume relativo:

1.00

Capitalizzazione di mercato:

$21.86B

Reddito:

$14.57B

Utile/perdita netta:

-$296.50M

Rapporto P/E:

EPS:

-$0.259

Flusso di cassa netto:

$1.64B

1W Prestazione:

+4.07%

1M Prestazione:

+8.15%

6M Prestazione:

+26.56%

1Y Prestazione:

+83.74%

Intervallo 1D:

$0.00$0.00

Intervallo di 1 settimana:

$18.17$19.51

Portata 52W:

$9.92$19.51

Profilo aziendale di Viatris Inc (VTRS)

Nome

Viatris Inc

Settore

Healthcare

Industria

Drug Manufacturers - Specialty & Generic

Telefono

(724) 514-1465

Indirizzo

1000 MYLAN BOULEVARD, CANONSBURG, USA

Dipendente

30,000

Prossima data di guadagno

2026-11-05

Ultimi documenti SEC

SEC

Discussioni di VTRS su X

Confronta VTRS con TAK, TEVA, HLN, ZTS, UTHR

Azioni	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	$21.86B	$14.57B	-$296.50M	$1.64B	-$0.259
TAK Takeda Pharmaceutical Co Adr	$66.81B	$29.91B	$1.30B	$3.49B	$0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	$49.09B	$17.53B	$1.58B	$444.18M	$1.35
HLN Haleon Plc Adr	$38.08B	$14.54B	$2.22B	$2.58B	$0.4871
ZTS Zoetis Inc	$32.94B	$9.51B	$2.64B	$2.14B	$6.04
UTHR United Therapeutics Corp	$25.68B	$3.17B	$1.29B	$1.01B	$27.09

Viatris Inc Azioni (VTRS) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-09-23	Iniziato	Oppenheimer	Outperform
2026-09-09	Iniziato	Leerink Partners	Outperform
2026-02-09	Aggiornamento	UBS	Neutral → Buy
2026-01-16	Aggiornamento	Argus	Hold → Buy
2025-12-09	Iniziato	Barclays	Overweight
2025-10-15	Iniziato	Truist	Buy
2025-06-06	Iniziato	Goldman	Neutral
2024-07-19	Resumed	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Resumed	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Resumed	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Viatris Inc Azioni (VTRS) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	14,299.90	14,739.30	15,426.90	16,262.70	17,886.30
Cost of revenue USD (M)	9,286.40	9,115.70	8,988.30	9,765.70	12,310.80
Gross profit USD (M)	5,013.50	5,623.60	6,438.60	6,497.00	5,575.50
Research and development USD (M)	-	-	-	-	751.10
Operating expenses USD (M)	7,676.60	5,613.50	5,672.40	4,882.10	5,609.50
Operating income USD (M)	-2,663.10	10.10	766.20	1,614.90	-34.00
Income before tax USD (M)	-3,665.00	-623.20	202.90	2,813.20	-664.40
Income tax expense USD (M)	-150.10	11.00	148.20	734.60	604.70
Net income USD (M)	-3,514.90	-634.20	54.70	2,078.60	-1,269.10
Basic EPS USD/shares	-3.00	-0.53	0.05	1.71	-1.05
Diluted EPS USD/shares	-3.00	-0.53	0.05	1.71	-1.05
Basic weighted shares shares (M)	-	-	-	1,212.10	1,208.80
Diluted weighted shares shares (M)	-	-	-	1,217.40	1,208.80
Selling, general and administrative USD (M)	3,794.10	4,425.60	4,650.10	4,179.10	4,529.20

Viatris Inc Azioni (VTRS) insider trading

Paul CampbellJun 25 '26
Officer
Transazione
Proposed Sale
Costo
$16.17
#Azioni
50,076
Valore ($)
809,678
#Azioni Totale
0
Campbell PaulJun 25 '26
See Remarks
Transazione
Sale
Costo
$16.17
#Azioni
50,076
Valore ($)
809,784
#Azioni Totale
316,212
Le Goff CorinneApr 15 '26
Chief Commercial Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
42,988
Valore ($)
0
#Azioni Totale
122,558
Campbell PaulMar 23 '26
See Remarks
Transazione
Sale
Costo
$13.28
#Azioni
21,350
Valore ($)
283,539
#Azioni Totale
366,288
Paul CampbellMar 23 '26
Officer
Transazione
Proposed Sale
Costo
$13.28
#Azioni
21,350
Valore ($)
283,508
#Azioni Totale
0
MARK RICHARD AMar 06 '26
Director
Transazione
Option Exercise
Costo
$0.00
#Azioni
24,835
Valore ($)
0
#Azioni Totale
116,145
Campbell PaulMar 06 '26
See Remarks
Transazione
Option Exercise
Costo
$0.00
#Azioni
28,974
Valore ($)
0
#Azioni Totale
398,956
Smith Scott AndrewMar 06 '26
Chief Executive Officer
Transazione
Option Exercise
Costo
$0.00
#Azioni
130,701
Valore ($)
0
#Azioni Totale
1,374,576
HIGGINS MELINA EMar 06 '26
Director
Transazione
Option Exercise
Costo
$0.00
#Azioni
24,835
Valore ($)
0
#Azioni Totale
146,048
Groothuis Leo FransMar 06 '26
Director
Transazione
Option Exercise
Costo
$0.00
#Azioni
24,835
Valore ($)
0
#Azioni Totale
63,567

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Paul Campbell	Officer	Jun 25 '26	Proposed Sale	$16.17	50,076	809,678	0
Campbell Paul	See Remarks	Jun 25 '26	Sale	$16.17	50,076	809,784	316,212
Le Goff Corinne	Chief Commercial Officer	Apr 15 '26	Option Exercise	$0.00	42,988	0	122,558
Campbell Paul	See Remarks	Mar 23 '26	Sale	$13.28	21,350	283,539	366,288
Paul Campbell	Officer	Mar 23 '26	Proposed Sale	$13.28	21,350	283,508	0
MARK RICHARD A	Director	Mar 06 '26	Option Exercise	$0.00	24,835	0	116,145
Campbell Paul	See Remarks	Mar 06 '26	Option Exercise	$0.00	28,974	0	398,956
Smith Scott Andrew	Chief Executive Officer	Mar 06 '26	Option Exercise	$0.00	130,701	0	1,374,576
HIGGINS MELINA E	Director	Mar 06 '26	Option Exercise	$0.00	24,835	0	146,048
Groothuis Leo Frans	Director	Mar 06 '26	Option Exercise	$0.00	24,835	0	63,567

Viatris Inc Borsa (VTRS) Ultime notizie

Oct 30, 2026

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats - Zacks Investment Research

Oct 30, 2026

Oct 27, 2026

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Oct 27, 2026

Oct 26, 2026

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Oct 26, 2026

Oct 16, 2026

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.

Oct 16, 2026

What US Small Cap Value Portfolio ETF (DFSV) Bought: Dick's Leads on Wednesday - Yahoo Finance

Oct 16, 2026

Oct 13, 2026

Form 4 Viatris Inc: David S. Simmons (Director) For: 30 September - Investing.com UK

Oct 13, 2026

Oct 09, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView

Oct 09, 2026

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research

Oct 09, 2026

Viatris to Acquire Pacira in $1.65 Billion Deal - Contract Pharma

Oct 09, 2026

Oct 08, 2026

An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan

Oct 08, 2026

Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada

Oct 08, 2026

Pacira BioSciences jumps 44% after Viatris agre... - Pluang

Oct 08, 2026

Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com

Oct 08, 2026

Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com

Oct 08, 2026

Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart

Oct 08, 2026

Why Pacira BioSciences Skyrocketed Today - The Motley Fool

Oct 08, 2026

A $36.50-a-share cash deal would add a wholly owned subsidiary to Viatris (VTRS). - Stock Titan

Oct 08, 2026

Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com South Africa

Oct 08, 2026

Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India

Oct 08, 2026

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom

Oct 08, 2026

Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc. - Ashurst Perkins Coie

Oct 08, 2026

Doubling up in pain: Viatris pays $1.65B, Pacira gets relief - BioWorld News

Oct 08, 2026

Viatris to acquire Pacira BioSciences for $1.65 billion - Investing.com

Oct 08, 2026

Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive

Oct 08, 2026

Oct 06, 2026

VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research

Oct 06, 2026

Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research

Oct 06, 2026

Oct 05, 2026

Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research

Oct 05, 2026

Oct 04, 2026

Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK

Oct 04, 2026

Oct 03, 2026

Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research

Oct 02, 2026

Oct 01, 2026

Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research

Oct 01, 2026

Sep 29, 2026

More than 300,000 people took part in Forbes' employer survey; Viatris made the list. - Stock Titan

Sep 29, 2026

Sep 28, 2026

Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street

Sep 28, 2026

Sep 21, 2026

Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK

Sep 21, 2026

Sep 17, 2026

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView

Sep 17, 2026

Sep 16, 2026

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView

Sep 16, 2026

Sep 10, 2026

Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress

Sep 10, 2026

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Sep 10, 2026

Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress

Sep 10, 2026

Viatris, Long Chau launch lipid disorder management campaign - VnExpress International

Sep 10, 2026

Sep 09, 2026

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha

Sep 09, 2026

VTRS - Finviz

Sep 09, 2026

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Sep 09, 2026

Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com

Sep 09, 2026

Sep 08, 2026

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Sep 08, 2026

Viatris gets 11% passive stake disclosed by FMR | VTRS SEC Filing - Form SCHEDULE 13G/A - Stock Titan

Sep 08, 2026

Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo

Sep 08, 2026

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com

Sep 08, 2026

Simile a VTRS

Viatris Inc (VTRS)

Profilo aziendale di Viatris Inc (VTRS)

Confronta VTRS con TAK, TEVA, HLN, ZTS, UTHR

Viatris Inc Azioni (VTRS) Upgrade e downgrade

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc Azioni (VTRS) insider trading

Viatris Inc Borsa (VTRS) Ultime notizie

4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats - Zacks Investment Research

Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research

Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewswire Inc.

What US Small Cap Value Portfolio ETF (DFSV) Bought: Dick's Leads on Wednesday - Yahoo Finance

Form 4 Viatris Inc: David S. Simmons (Director) For: 30 September - Investing.com UK

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - TradingView

Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio - Zacks Investment Research

Viatris to Acquire Pacira in $1.65 Billion Deal - Contract Pharma

An offer for all Pacira BioSciences (PCRX) shares is planned but has not yet begun. - Stock Titan

Lumen Technologies, Inc. Common Stock (LUMN) Stock Forecasts - Yahoo! Finance Canada

Pacira BioSciences jumps 44% after Viatris agre... - Pluang

Pacira BioSciences (Nasdaq: PCRX) Makes 52 Week High on Acquisition News - Investorideas.com

Viatris Inc. entered into a definitive agreement to acquire Pacira BioSciences, Inc. for $1.6 billion. - marketscreener.com

Viatris to Acquire Pacira BioSciences for $36.50 Per Share in $1.65 Billion Cash Deal - Minichart

Why Pacira BioSciences Skyrocketed Today - The Motley Fool

A $36.50-a-share cash deal would add a wholly owned subsidiary to Viatris (VTRS). - Stock Titan

Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com South Africa

Viatris to acquire Pacira BioSciences for $1.65 billion By Investing.com - Investing.com India

Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies - Viatris Newsroom

Ashurst Perkins Coie advises Pacira BioSciences, Inc. on its $1.65 billion acquisition by Viatris Inc. - Ashurst Perkins Coie

Doubling up in pain: Viatris pays $1.65B, Pacira gets relief - BioWorld News

Viatris to acquire Pacira BioSciences for $1.65 billion - Investing.com

Viatris Acquires Pacira BioSciences for $1.65 Billion - Pharmaceutical Executive

VTRS vs. AVTR: Which Stock Is the Better Value Option? - Zacks Investment Research

Should Value Investors Buy Viatris (VTRS) Stock? - Zacks Investment Research

Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy? - Zacks Investment Research

Lumen Technologies, Inc. Common Stock (LUMN) stock price, news, quote and history - Yahoo Finance UK

Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com Nigeria

Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com South Africa

Form 4 Viatris Inc For: 3 October By Investing.com - Investing.com UK

Is WisdomTree U.S. MidCap Dividend ETF (DON) a Strong ETF Right Now? - Zacks Investment Research

Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research

More than 300,000 people took part in Forbes' employer survey; Viatris made the list. - Stock Titan

Viatris (NasdaqGS:VTRS) Stock Forecast & Analyst Predictions - Simply Wall Street

Viatris Inc. (VTRS) stock price, news, quote and history - Yahoo Finance UK

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 - TradingView

Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 - TradingView

Here's Why Viatris (VTRS) is a Strong Value Stock - Eastern Progress

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Here's Why Viatris (VTRS) is a Strong Momentum Stock - Eastern Progress

Viatris, Long Chau launch lipid disorder management campaign - VnExpress International

Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha

VTRS - Finviz

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress

Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com

Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch

Viatris gets 11% passive stake disclosed by FMR | VTRS SEC Filing - Form SCHEDULE 13G/A - Stock Titan

Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo

Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - marketscreener.com

Simile a VTRS